Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule allosteric modulators to treat neurological disorders, with operations in Switzerland and the United States. The company's core business centers on its proprietary drug discovery technology platform that enables development of novel neurological therapeutics, and it generates revenue through licensing arrangements with development partners, contract research services, and royalty streams from potential future commercialized products. As a development-stage enterprise, Addex relies primarily on equity financing to fund operations and maintains strategic partnerships and minority investments in emerging biotech companies to advance its pipeline and support financial sustainability.